Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the final close of its sixth fund at $439 million.
Joining existing investors Hesta, Host Plus, CSL, QIC is the Western Australian Government and Australia’s sovereign investor in manufacturing capability, the National Reconstruction Fund Corporation (NRFC).
Brandon Capital stated that the final close of its Fund Six (BB6) will enable it to continue investing in emerging biomedical technologies with strong commercial potential, translating these exciting discoveries into high-growth firms that positively impact human health.
To date, Brandon Capital has raised over $1 billion across its previous funds, with notable investments in Fund Six, including AdvanCell (radiopharma), PolyActiva (glaucoma implant), Myricx Bio (ADC), and CatalYm (oncology).
Dr Chris Nave, Co-Founder and Managing Partner at Brandon Capital, said, “We’re excited to welcome the National Reconstruction Fund Corporation to our sixth fund, joining HESTA, Hostplus, CSL, QIC and the WA Government. Closing at $439 million, BB6 is our largest fund to date, and we remain committed to advancing breakthrough biomedical innovations through our unwavering scientific rigour and disciplined capital allocation, in pursuit of exceeding our investors’ expectations.”
Recent Brandon Capital portfolio company announcements include FDA approvals for a hypertension therapy from George Medicines and a left ventricular cardiac resynchronisation device developed by EBR Systems, as well as Q-Sera’s blood collection tubes, which produce high-quality serum faster and more reliably, and have recently been approved in Japan.
Brandon Capital has an active portfolio of over 30 companies with 17 in clinical trials, four advancing or in-market, a promising preclinical pipeline, and several actively contributing to Australia’s high-skilled manufacturing sector growth.
NRFC CEO David Gall added, “Medical science has long development timelines, and it is important for the NRFC to make early and considered investments in the sector to attract the talent and capital that we will need to build our local commercialisation capabilities. If we want medical science jobs and industries to exist in Australia in ten years, we need to invest in them today.”